Dual Antiplatelet Therapy vs Alteplase for Patients With Minor Nondisabling Acute Ischemic Stroke: The ARAMIS Randomized Clinical Trial.

Importance: Intravenous thrombolysis is increasingly used in patients with minor stroke, but its benefit in patients with minor nondisabling stroke is unknown.

Objective: To investigate whether dual antiplatelet therapy (DAPT) is noninferior to intravenous thrombolysis among patients with minor nondisabling acute ischemic stroke.

Design, Setting, And Participants: This multicenter, open-label, blinded end point, noninferiority randomized clinical trial included 760 patients with acute minor nondisabling stroke (National Institutes of Health Stroke Scale [NIHSS] score ≤5, with ≤1 point on the NIHSS in several key single-item scores; scale range, 0-42).

Synthesis, crystal structures, and catalytic oxidation properties of oxidovanadium(V) complexes with hydrazone and hydroxamate ligands.

Two new oxidovanadium(V) complexes with hydrazone ligands and hydroxamate ligands were synthesized and characterized by IR and (1)H NMR spectroscopy, elemental analysis and single crystal X-ray diffraction. The coordination sphere of each V atom is octahedral, constructed from three donor atoms of the hydrazone ligand, two donor atoms of the hydroxamate ligand, and one oxido oxygen. Both complexes show effective catalytic oxidation properties for the oxidation of cyclohexene, cyclopentene and benzyl alcohol using H(2)O(2) as primary oxidant.